|
18 Apr 2021
Disclosure to EGX on EGM and OGM minutes
|
Q2 |
2021 |
|
|
07 Apr 2021
EGX Disclosure on BOD and shareholding structure
|
Q1 |
2021 |
|
|
28 Mar 2021
EGX disclosure regarding the upcoming EGM/OGM on 18 April 2021
|
Q1 |
2021 |
|
|
25 Mar 2021
EGX Disclosure regarding Rameda's Governance Report
|
Q1 |
2021 |
|
|
22 Mar 2021
Disclosure to EGX correcting the number of BoD meetings in the Annual BoD Report
|
Q1 |
2021 |
|
|
09 Feb 2021
Disclosure to EGX on GlaxoSmithKline S.A.E response to Rameda's acquisition request
|
Q1 |
2021 |
|
|
03 Feb 2021
Disclosure to EGX on Rameda expressing interest in the acquisition of GlaxoSmithKline S.A.E
|
Q1 |
2021 |
|
|
14 Jan 2021
Disclosure to EGX on FRA approval of new a remuneration system
|
Q1 |
2021 |
|
|
13 Jan 2021
EGX Disclosure on BOD and shareholding structure
|
Q4 |
2020 |
|
|
06 Dec 2020
EGX disclosure on changes to company policy
|
Q4 |
2020 |
|
|
25 Nov 2020
Disclosure to EGX regarding the contact information for Investor Relations department
|
Q4 |
2020 |
|
|
11 Nov 2020
Disclosure to EGX on BOD minutes
|
Q3 |
2020 |
|
|
15 Oct 2020
Summary of AGM Decisions – 14 October 2020
|
Q3 |
2020 |
|
|
15 Oct 2020
Disclosure to EGX on EGM minutes
|
Q3 |
2020 |
|
|
12 Oct 2020
Disclosure to EGX on BOD minutes
|
Q3 |
2020 |
|
|
12 Oct 2020
EGX Disclosure on BOD and shareholding structure
|
Q3 |
2020 |
|
|
21 Sep 2020
EGX disclosure regarding the upcoming EGM on 14 October 2020
|
Q3 |
2020 |
|
|
17 Sep 2020
Disclosure to EGX regarding the failure to reach quorum for the company’s EGM
|
Q3 |
2020 |
|
|
01 Sep 2020
Disclosure to EGX on OGM minutes
|
Q3 |
2020 |
|
|
26 Aug 2020
EGX disclosure regarding the upcoming EGM on 17 September 2020
|
Q3 |
2020 |
|
|
05 Aug 2020
Disclosure to EGX regarding the company's board composition
|
Q3 |
2020 |
|
|
14 Jul 2020
Disclosure to EGX on BOD minutes
|
Q3 |
2020 |
|
|
09 Jul 2020
EGX Disclosure on BOD and shareholding structure
|
Q2 |
2020 |
|
|
22 Jun 2020
EGX disclosure regarding Rameda's manufacturing of “Anviziram” Tablets the Generic Equivalent of Japanese antiviral Avigan for treatment of Covid-19 patients and receives approval from Egyptian Drug Authority to manufacture Remedsivir
|
Q2 |
2020 |
|
|
14 May 2020
Rameda AGM Minutes of Meeting- 10 May 2020 (Before Certification)
|
Q2 |
2020 |
|
|
11 May 2020
Summary of AGM Decisions – 10 May 2020
|
Q2 |
2020 |
|
|
22 Apr 2020
EGX Disclosure regarding Rameda's Governance Report
|
Q2 |
2020 |
|
|
15 Apr 2020
EGX disclosure regarding the upcoming AGM on 10 May 2020
|
Q1 |
2020 |
|
|
14 Apr 2020
EGX Disclosure on BOD and shareholding structure
|
Q1 |
2020 |
|
|
01 Apr 2020
EGX disclosure announcing the acquisition of a generic anti-inflammatory analgesic molecule
|
Q1 |
2020 |
|
|
24 Mar 2020
EGX disclosure regarding the postponement of the OGM
|
Q1 |
2020 |
|
|
01 Mar 2020
EGX disclosure regarding the upcoming OGM on 25 March 2020
|
Q1 |
2020 |
|
|
12 Feb 2020
EGX Disclosure on BOD and shareholding structure
|
Q4 |
2019 |
|
|
13 Feb 2020
EGX Disclosure on BOD and shareholding structure
|
Q1 |
2020 |
|
|
14 Jan 2020
Disclosure to EGX on BOD and shareholding structure as of 31 December 2019
|
Q4 |
2019 |
|
|
01 Dec 2019
Disclosure to EGX on EGM and BOD minutes
|
Q4 |
2019 |
|
